CL2009000742A1 - Forma solida cristalina de clorhidrato de bendamustina, designada como forma 1; composicion farmaceutica que la comprende; metodo de preparacion de la composicion farmaceutica; y uso en el tratamiento de leucemia linfocitica cronica, enfermedad de hodgkin, linfoma no hodgkiniano, mieloma multiple o cancer de mama. - Google Patents

Forma solida cristalina de clorhidrato de bendamustina, designada como forma 1; composicion farmaceutica que la comprende; metodo de preparacion de la composicion farmaceutica; y uso en el tratamiento de leucemia linfocitica cronica, enfermedad de hodgkin, linfoma no hodgkiniano, mieloma multiple o cancer de mama.

Info

Publication number
CL2009000742A1
CL2009000742A1 CL2009000742A CL2009000742A CL2009000742A1 CL 2009000742 A1 CL2009000742 A1 CL 2009000742A1 CL 2009000742 A CL2009000742 A CL 2009000742A CL 2009000742 A CL2009000742 A CL 2009000742A CL 2009000742 A1 CL2009000742 A1 CL 2009000742A1
Authority
CL
Chile
Prior art keywords
hodgkin
pharmaceutical composition
lymphoma
disease
preparation
Prior art date
Application number
CL2009000742A
Other languages
English (en)
Inventor
Martin Ian Cooper
Laurent Courvoisier
Mark Eddleston
Robert E Mckean
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41051023&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009000742(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of CL2009000742A1 publication Critical patent/CL2009000742A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Abstract

Forma sólida de clorhidrato de bendamustina; composición farmacéutica; método de preparación y su uso en la leucemia linfocitica crónica, Enfermedad de Hodgkin, Linfoma no Hodgkiniano, mieloma múltiple, cáncer de mama.
CL2009000742A 2008-03-26 2009-03-26 Forma solida cristalina de clorhidrato de bendamustina, designada como forma 1; composicion farmaceutica que la comprende; metodo de preparacion de la composicion farmaceutica; y uso en el tratamiento de leucemia linfocitica cronica, enfermedad de hodgkin, linfoma no hodgkiniano, mieloma multiple o cancer de mama. CL2009000742A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3975208P 2008-03-26 2008-03-26

Publications (1)

Publication Number Publication Date
CL2009000742A1 true CL2009000742A1 (es) 2009-11-13

Family

ID=41051023

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000742A CL2009000742A1 (es) 2008-03-26 2009-03-26 Forma solida cristalina de clorhidrato de bendamustina, designada como forma 1; composicion farmaceutica que la comprende; metodo de preparacion de la composicion farmaceutica; y uso en el tratamiento de leucemia linfocitica cronica, enfermedad de hodgkin, linfoma no hodgkiniano, mieloma multiple o cancer de mama.

Country Status (12)

Country Link
US (9) US20090264488A1 (es)
EP (2) EP2271315B1 (es)
JP (1) JP5536753B2 (es)
CN (3) CN105693620A (es)
AR (1) AR072777A1 (es)
CA (1) CA2718939A1 (es)
CL (1) CL2009000742A1 (es)
ES (1) ES2605205T3 (es)
HK (1) HK1220966A1 (es)
MX (2) MX339878B (es)
TW (1) TWI472515B (es)
WO (1) WO2009120386A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
EP2583670A1 (en) * 2007-10-09 2013-04-24 US Worldmeds LLC Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
AU2009296734B2 (en) * 2008-09-25 2016-02-18 Cephalon Llc Liquid formulations of bendamustine
UA107186C2 (xx) * 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
WO2010144675A1 (en) * 2009-06-10 2010-12-16 Plus Chemicals Sa Polymorphs of bendamustine hcl and processes for preparation thereof
US9376394B2 (en) 2009-12-23 2016-06-28 Dr. Reddy's Laboratories Ltd. Preparation of bendamustine and its salts
SI3158991T1 (sl) 2010-01-28 2021-10-29 Eagle Pharmaceuticals Inc Formulacije bendamustina
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
MX2012013872A (es) 2010-06-02 2013-04-03 Astellas Deutschland Gmbh Formas de dosificacion oral de bendamustina.
CN101948437B (zh) * 2010-06-28 2012-08-29 江苏奥赛康药业股份有限公司 一种盐酸苯达莫司汀的精制方法
US20130217888A1 (en) * 2010-11-01 2013-08-22 Shailpa Medicare Limited Process for preparing bendamus tine hydrochloride monohydrate
US20140142153A1 (en) * 2011-01-25 2014-05-22 Dr. Reddy's Laboratories, Inc. Bendamustine formulations
CA2819017A1 (en) * 2011-01-31 2012-08-09 Cephalon, Inc. Methods for the preparation of bendamustine
EP2760842B1 (en) 2011-09-26 2016-11-16 Fresenius Kabi Oncology Ltd An improved process for the preparation of bendamustine hydrochloride
CN102351799B (zh) * 2011-10-24 2014-02-26 江苏奥赛康药业股份有限公司 一种盐酸苯达莫司汀晶型及其制备方法
EP2617716A1 (en) 2012-01-18 2013-07-24 Arevipharma GmbH Process for the preparation of bendamustine hydrochloride and related compounds
ES2943668T3 (es) * 2012-03-20 2023-06-15 Eagle Pharmaceuticals Inc Composiciones líquidas de bendamustina para su uso en un método para tratar afecciones que responden a la bendamustina en pacientes que requieren volúmenes reducidos para administración
FI2827862T3 (fi) 2012-03-20 2024-02-13 Eagle Pharmaceuticals Inc Bendamustiinin formulaatioita
WO2013150020A1 (en) 2012-04-03 2013-10-10 Synthon Bv Process for making bendamustine
DK2656843T3 (en) 2012-04-26 2015-04-20 Helmut Schickaneder Esters of bendamustine and related compounds, and medical use thereof
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9801859B2 (en) * 2012-09-18 2017-10-31 Innopharma Licensing, Llc Bendamustine formulations
TWI598341B (zh) 2012-11-12 2017-09-11 伊格尼塔公司 苯達莫司汀衍生物及其使用方法
WO2014127802A1 (en) 2013-02-19 2014-08-28 Synthon Bv Stable compositions of bendamustine
US9315469B2 (en) 2013-03-14 2016-04-19 Johnson Matthey Public Limited Company Process for drying bendamustine hydrochloride monohydrate
WO2014170769A2 (en) * 2013-04-15 2014-10-23 Shilpa Medicare Limited Bendamustine lyophilized pharmaceutical compositions
CN105491886B (zh) 2013-08-27 2019-01-29 V·沃道里斯 苯达莫司汀医药组合物
WO2015138199A1 (en) * 2014-03-13 2015-09-17 Voudouris Vasilios Bendamustine solid dispersions and continuous infusion
EP2985038A1 (en) 2014-08-12 2016-02-17 Azad Pharma AG Lyophilized API preparation
US10342769B2 (en) 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
US9603930B2 (en) 2014-12-04 2017-03-28 Navinta, Llc Liquid bendamustine formulation
ES2889902T3 (es) * 2015-06-09 2022-01-14 Rebiotix Inc Métodos de fabricación de composiciones para terapia de restauración de la microbiota (TRM)
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
CN111201019A (zh) 2017-10-05 2020-05-26 图贝药物有限公司 口服苯达莫司汀制剂
CN111093654B (zh) * 2017-11-07 2023-03-10 江苏恒瑞医药股份有限公司 一种盐酸苯达莫司汀的晶体及其制备方法
EA037673B1 (ru) * 2018-07-04 2021-04-29 Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции, содержащей бендамустин, фармацевтическая композиция бендамустина
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CA3235585A1 (en) 2021-10-22 2023-04-27 Andreas Schutz Liquid pharmaceutical formulation

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE80967C (es)
DE34727C (de) Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue Verfahren zur direkten Gewinnung metallischen Bleis
DE159877C (es) *
DD80967A (es)
DE293808C (es)
DE159289C (es) 1903-10-08 1905-03-16
DD34727A1 (de) 1963-12-21 1964-12-28 Dietrich Krebs Verfahren zur Herstellung von 1-Stellung substituierten [5-Bis-(chloräthyl)-amino-benzimidazolyl-(2)]-alkancarbonsäuren
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
US4012448A (en) 1976-01-15 1977-03-15 Stanford Research Institute Synthesis of adriamycin and 7,9-epiadriamycin
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DD159877A1 (de) * 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US5227374A (en) 1982-11-12 1993-07-13 Mead Johnson & Company Lyophilized cyclophosphamide
US4659699A (en) 1983-08-22 1987-04-21 Cetus-Ben Venue Therapeutics Process for freeze drying cyclophosphamide
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US4879286A (en) 1987-01-28 1989-11-07 Lyphomed, Inc. Cyclophosphamide
DE58900183D1 (de) 1988-03-19 1991-08-29 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung.
DE3907079A1 (de) 1988-03-19 1989-09-28 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung
US5036060A (en) 1988-07-25 1991-07-30 Fujisawa Usa, Inc. Cyclophosphamide
CA2001552C (en) 1988-11-14 1997-07-22 The Upjohn Company Cyclophosphamide - sodium bicarbonate lyophilizates
US5066647A (en) 1989-04-20 1991-11-19 Erbamont, Inc. Cyclophosphamide - alanine lyophilizates
US5051257A (en) 1989-05-09 1991-09-24 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
DD293808A5 (de) 1990-04-23 1991-09-12 Zi Fuer Mikrobiologie Uns Experimentelle Therapie,De Verfahren zur herstellung von (5-[bis(2-chlorethyl)amino]-1-methyl-benzimidazolyl(2)ethansaeurealkylestern
US5268368A (en) 1991-05-17 1993-12-07 Erbamont, Inc. Cyclophosphamide--amino acid lyophilizates
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
US5192743A (en) 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
CA2149329C (en) * 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US5418223A (en) 1993-05-20 1995-05-23 Erbamont, Inc. Method for lyophilization of cyclophosphamide and product
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
DK0725642T3 (da) * 1993-10-27 2000-05-29 Upjohn Co Stabiliseret prostaglandin E1
US5561121A (en) 1993-11-09 1996-10-01 American Cyanamid Company Stable lyophilized thiotepa composition
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
WO1997008174A1 (en) 1995-08-31 1997-03-06 Smithkline Beecham Corporation Interleukin converting enzyme and apoptosis
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
EA200000087A1 (ru) 1997-07-01 2000-08-28 Атеродженикс, Инк. Повышение эффективности терапии гиперпролиферативных состояний с помощью антиоксиданта
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
ATE315392T1 (de) * 1998-07-09 2006-02-15 Francis A Nardella Zusammensetzungen zur behandlung chronischer lymphatischer leukämie
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) * 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
DE10016077A1 (de) 2000-03-31 2001-12-13 Cellcontrol Biomedical Lab Gmb Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen
AUPQ849900A0 (en) 2000-06-30 2000-07-27 Dbl Australia Pty Ltd. Injectable composition
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
HUP0400683A2 (hu) * 2000-12-11 2004-06-28 Takeda Chemical Industries, Ltd. HER2 inhibitort tartalmazó fokozott felszívódású gyógyászati készítmény
US20040058956A1 (en) * 2000-12-11 2004-03-25 Yohko Akiyama Pharmaceutical composition having an improved water solubility
WO2002080996A1 (de) * 2001-04-03 2002-10-17 Franz Herbst Medizinisches implantat und verfahren zu seiner herstellung
DK1435877T3 (da) * 2001-10-15 2009-08-03 Hemoteq Ag Overtrækning af stents for at forhindre restenose
US6613927B1 (en) 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
DE10306724A1 (de) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
CN100561229C (zh) 2002-03-22 2009-11-18 克里斯蒂安·施特拉卡 细胞能力检验
EP1354952A1 (en) 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1495124A2 (en) 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
WO2003094991A1 (de) * 2002-05-09 2003-11-20 Hemoteq Gmbh Hemokompatibel beschichtete medizinprodukte, deren herstellung und verwendung
US20040096436A1 (en) * 2002-08-02 2004-05-20 Regents Of The University Of California Methods for inhibiting protein kinases in cancer cells
NZ540318A (en) 2002-10-31 2007-09-28 Umd Inc Therapeutic compositions for drug delivery to and through covering epithelia
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
US7157551B2 (en) * 2003-02-14 2007-01-02 Cephalon, Inc. Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
BRPI0412916A (pt) * 2003-07-25 2006-09-26 Wyeth Corp formulações liofilizadas de cci-779
EP1814544A4 (en) * 2004-11-05 2009-12-02 Cephalon Inc CANCER TREATMENTS
JP2008520652A (ja) 2004-11-22 2008-06-19 ヴィーナス・レメディーズ・リミテッド 非水性液状の非経口的アセクロフェナク製剤
EP1674081A1 (de) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
UA94036C2 (ru) * 2005-01-14 2011-04-11 Сефалон, Инк. Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
ATE509634T1 (de) 2005-04-08 2011-06-15 Amylin Pharmaceuticals Inc Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
ITUD20070130A1 (it) 2007-07-23 2009-01-24 C M E Spa Sa Macchina e procedimento per la produzione di elementi strutturali per l'edilizia in materiale cementizio aventi uno o piu' inserti in materiale polimerico
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
AU2009296734B2 (en) 2008-09-25 2016-02-18 Cephalon Llc Liquid formulations of bendamustine
CA2760085A1 (en) 2009-04-28 2010-11-04 Cephalon, Inc. Oral formulations of bendamustine

Also Published As

Publication number Publication date
US20170071913A1 (en) 2017-03-16
US20090264488A1 (en) 2009-10-22
CA2718939A1 (en) 2009-10-01
US8669279B2 (en) 2014-03-11
MX2010010398A (es) 2010-12-20
HK1220966A1 (zh) 2017-05-19
JP2011515472A (ja) 2011-05-19
WO2009120386A2 (en) 2009-10-01
US20140187598A1 (en) 2014-07-03
US8883836B2 (en) 2014-11-11
US20190015390A1 (en) 2019-01-17
WO2009120386A3 (en) 2009-12-03
US20160159748A1 (en) 2016-06-09
CN101980698A (zh) 2011-02-23
EP2271315B1 (en) 2016-09-14
US20130245086A1 (en) 2013-09-19
US10039750B2 (en) 2018-08-07
CN105693620A (zh) 2016-06-22
US20150051258A1 (en) 2015-02-19
US20200323824A1 (en) 2020-10-15
US8445524B2 (en) 2013-05-21
TW200944508A (en) 2009-11-01
EP3150197A1 (en) 2017-04-05
MX339878B (es) 2016-06-15
EP2271315A2 (en) 2011-01-12
CN103550159A (zh) 2014-02-05
CN103550159B (zh) 2016-02-10
ES2605205T3 (es) 2017-03-13
JP5536753B2 (ja) 2014-07-02
AR072777A1 (es) 2010-09-22
TWI472515B (zh) 2015-02-11
US20120071532A1 (en) 2012-03-22
US9533955B2 (en) 2017-01-03
CN101980698B (zh) 2013-10-16
US10517852B2 (en) 2019-12-31

Similar Documents

Publication Publication Date Title
CL2009000742A1 (es) Forma solida cristalina de clorhidrato de bendamustina, designada como forma 1; composicion farmaceutica que la comprende; metodo de preparacion de la composicion farmaceutica; y uso en el tratamiento de leucemia linfocitica cronica, enfermedad de hodgkin, linfoma no hodgkiniano, mieloma multiple o cancer de mama.
SMT201600025B (it) Composti di isoindolina per l'uso nel trattamento del cancro
PE20160841A1 (es) Macrociclos como inhibidores del factor de coagulacion (fxia)
DE502008000766D1 (de) Blasmaschine mit Garniturteilhalter, sowie Garniturteilhalter
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
CL2007003627A1 (es) Compuestos derivados de 3-h-pirazolopiridinas; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades de crecimiento vascular desregulado tal como leucemia mielogena aguda, retinopatia, artritis reumatoide, psorias
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
BRPI0813680A2 (pt) AGENTES DE iRNA, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS MESMOS, BEM COMO SEU USO.
FR2903992B1 (fr) Composition de scintillateur, article et procede associe.
SV2011003949A (es) Compuesto amino pirazol
IT1390737B1 (it) Macchina per la realizzazione di articoli assorbenti.
UY30349A1 (es) Ligandos del receptor de acetilcolina de tipo nicotinico
BRPI1004922A2 (pt) composição farmacêutica, forma cristalina da base livre de bendamustina e método de tratamento de leucemia linfocítica crônica, doença de hodgkin, linfoma não-hodgkin, mieloma múltiplo ou câncer da mama
IT1395519B1 (it) Pezzo composito, nonche' impiego del pezzo composito
BRPI0808798A2 (pt) Fenoxifenilamidinas 3,5-dissubstituídas e seu uso como fungicidas
DE102009037293A8 (de) Verbesserter Werkstückträger, Verfahren zu seiner Herstellung und dessen Verwendung
CL2008001658A1 (es) Composicion farmaceutica que comprende mesilato de imatinib amorfo y un principio de formulacion que estabiliza la forma amorfa; y su uso para tratar leucemia mieloide cronica avanzada y recientemente diagnosticada, leucemia mielomonocitica cronica, glioblastoma multiforme, entre otras.
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
SV2010003501A (es) Fungicidas novedosos
DOP2009000285A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulacion sanguinea.
DOP2009000207A (es) Nueva forma de dosificación
BRPI0720323A2 (pt) composto, método de tratamento, composição farmacêutica e uso do composto
DE602008002124D1 (de) Verbundstoffarbeitsdrehbank
GT200600039A (es) Tiazolidinonas, su preparacion y su uso como medicamento